Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
34.9M
-
Shares change
-
+5.01M
-
Total reported value, excl. options
-
$1.07B
-
Value change
-
+$72.9M
-
Put/Call ratio
-
0.29
-
Number of buys
-
80
-
Number of sells
-
-64
-
Price
-
$30.70
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2016
186 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2016.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.9M shares
of 49.6M outstanding shares and own 70.38% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP, L.L.C. (5.69M shares), FMR LLC (3.46M shares), WELLINGTON MANAGEMENT GROUP LLP (2.37M shares), VANGUARD GROUP INC (2.33M shares), ORBIMED ADVISORS LLC (2.28M shares), JANUS CAPITAL MANAGEMENT LLC (2.21M shares), STATE STREET CORP (1.95M shares), Redmile Group, LLC (1.29M shares), Partner Fund Management, L.P. (1.14M shares), and AMERICAN CENTURY COMPANIES INC (950K shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.